Regentis Biomaterials (RGNT) closed its initial public offering of 1.25 million ordinary shares at $8 each for $10 million in gross proceeds, the company said Friday.
The shares began trading Dec. 4 on the NYSE American under the ticker RGNT.
Regentis said it will use the proceeds mainly to advance development of its GelrinC cartilage-repair therapy and for corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.